|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
188,370,000 |
Market
Cap: |
16.70(B) |
Last
Volume: |
1,778,607 |
Avg
Vol: |
1,398,026 |
52
Week Range: |
$76.22 - $99 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 811 |
Guru Rank Value : 0.9 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
3,625 |
Total Buy Value |
$0 |
$0 |
$0 |
$314,469 |
Total People Bought |
0 |
0 |
0 |
1 |
Total Buy Transactions |
0 |
0 |
0 |
1 |
Total Shares Sold |
159,588 |
275,693 |
319,053 |
656,089 |
Total Sell Value |
$13,270,852 |
$23,760,160 |
$27,661,182 |
$61,420,002 |
Total People Sold |
5 |
6 |
7 |
7 |
Total Sell Transactions |
10 |
21 |
27 |
56 |
End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Baffi Robert |
EVP, Technical Operations |
|
2012-05-08 |
4 |
A |
$0.00 |
$0 |
D/D |
16,000 |
100,413 |
|
- |
|
Mueller Brian |
VP, Corporate Controller |
|
2012-05-08 |
4 |
S |
$37.50 |
$589,050 |
D/D |
(15,708) |
13,684 |
|
- |
|
Mueller Brian |
VP, Corporate Controller |
|
2012-05-08 |
4 |
OE |
$11.74 |
$216,967 |
D/D |
15,708 |
29,392 |
|
- |
|
Mueller Brian |
VP, Corporate Controller |
|
2012-05-08 |
4 |
A |
$0.00 |
$0 |
D/D |
4,720 |
13,684 |
|
- |
|
Fuchs Henry J |
EVP, Chief Medical Officer |
|
2012-05-08 |
4 |
A |
$0.00 |
$0 |
D/D |
24,000 |
54,018 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2012-05-08 |
4 |
AS |
$36.52 |
$547,800 |
D/D |
(15,000) |
113,191 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2012-05-08 |
4 |
OE |
$9.86 |
$147,900 |
D/D |
15,000 |
128,191 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2012-05-07 |
4 |
AS |
$35.96 |
$179,800 |
D/D |
(5,000) |
113,191 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2012-05-07 |
4 |
OE |
$9.86 |
$49,300 |
D/D |
5,000 |
118,191 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2012-05-04 |
4 |
AS |
$36.00 |
$360,000 |
D/D |
(10,000) |
113,191 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2012-05-04 |
4 |
OE |
$9.86 |
$98,600 |
D/D |
10,000 |
123,191 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2012-05-03 |
4 |
AS |
$36.68 |
$366,800 |
D/D |
(10,000) |
113,191 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2012-05-03 |
4 |
OE |
$9.86 |
$98,600 |
D/D |
10,000 |
123,191 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2012-05-02 |
4 |
AS |
$35.72 |
$357,200 |
D/D |
(10,000) |
113,191 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2012-05-02 |
4 |
OE |
$9.86 |
$98,600 |
D/D |
10,000 |
123,191 |
|
- |
|
Baffi Robert |
EVP, Technical Operations |
|
2012-05-01 |
4 |
GA |
$0.00 |
$0 |
I/I |
920 |
5,402 |
|
- |
|
Baffi Robert |
EVP, Technical Operations |
|
2012-05-01 |
4 |
GD |
$0.00 |
$0 |
D/D |
920 |
55,186 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2012-05-01 |
4 |
AS |
$35.00 |
$699,920 |
D/D |
(20,000) |
113,191 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2012-05-01 |
4 |
OE |
$9.86 |
$197,200 |
D/D |
20,000 |
133,191 |
|
- |
|
Fuchs Henry J |
EVP, Chief Medical Officer |
|
2012-05-01 |
4 |
AS |
$34.99 |
$174,950 |
D/D |
(5,000) |
30,018 |
|
- |
|
Fuchs Henry J |
EVP, Chief Medical Officer |
|
2012-05-01 |
4 |
OE |
$11.05 |
$55,250 |
D/D |
5,000 |
35,018 |
|
- |
|
Cooper Jeffrey H |
SVP, Chief Financial Officer |
|
2012-04-30 |
4 |
A |
$19.35 |
$19,056 |
D/D |
985 |
41,089 |
|
- |
|
Aselage Steve |
EVP, Chief Business Officer |
|
2012-04-30 |
4 |
A |
$19.35 |
$19,462 |
D/D |
1,006 |
47,685 |
|
- |
|
Wood Mark |
VP, Human Resources |
|
2012-04-30 |
4 |
A |
$27.91 |
$13,395 |
D/D |
480 |
21,114 |
|
- |
|
Davis George Eric |
SVP, General Counsel |
|
2012-04-30 |
4 |
A |
$19.35 |
$18,959 |
D/D |
980 |
40,631 |
|
- |
|
1317 Records found
|
|
Page 22 of 53 |
|
|